Dispatch Bio debuted as a new biotech utilizing a viral vector platform named Flare to tag solid tumor cells with a universal antigen, promoting immune clearance without harming healthy tissue. Backed by $216 million in funding led by Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, the approach aims to overcome immune suppression and antigen heterogeneity challenges in solid tumors. The company is co-founded by CAR-T pioneer Carl June and expects to enter clinical trials in 2026.